H.R. 9778House118th Congress (2023-2025)In Committee

PAVE Act

Introduced September 24, 2024

AI-Generated Summary

Updated January 20, 2026 at 7:14 PM UTC

The Penicillin Allergy Verification and Evaluation (PAVE) Act amends the Social Security Act so that Medicare’s initial preventive physical exam and annual wellness visit must include checking and evaluating any reported penicillin allergy. It defines how providers should identify, assess, educate about, and refer patients with a penicillin allergy label. The changes apply to Medicare beneficiaries starting January 1, 2025.

Key Provisions

  • Requires penicillin allergy verification and evaluation to be part of the initial preventive physical exam for Medicare seniors
  • Adds the same penicillin allergy verification and evaluation requirement to the annual wellness visit
  • Defines the verification process: identify reported allergy, review reaction history, provide information on health impacts, and refer to an allergy specialist as needed
  • Allows separate payment for structured penicillin allergy validation services performed on the same day as the exam or visit
  • Effective for examinations and visits provided on or after January 1, 2025

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

December 17, 2024

View full timeline
HouseIntro Referral

Introduced in House

September 24, 2024

HouseIntro Referral

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

September 24, 2024

HouseCommittee

Referred to the Subcommittee on Health.

December 17, 2024

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued September 24, 2024

I

118th CONGRESS

2d Session

H. R. 9778

IN THE HOUSE OF REPRESENTATIVES

September 24, 2024

Mr. Bucshon (for himself, Mr. Bera, Mr. Griffith, Mr. Peters, Mr. Murphy, Ms. Schrier, Mr. Kelly of Pennsylvania, Ms. DelBene, Mrs. Miller-Meeks, and Ms. Underwood) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to include penicillin allergy verification and evaluation as part of the initial preventive physical examination under the Medicare program.

1.

Short title

This Act may be cited as the Penicillin Allergy Verification and Evaluation Act or the PAVE Act.

2.

Findings

Congress makes the following:

(1)

On September 28, 1928, Alexander Fleming, a Scottish bacteriologist, discovered penicillin, forever changing healthcare by identifying an effective way to treat a wide range of infections which opened the doctor for numerous successful medical treatments.

(2)

Millions of patients believe they are allergic to penicillin, but information cited by the Centers for Disease Control and Prevention and recent medical journal articles in the Journal of the American Medical Association and the Journal of Allergy and Clinical Immunology, shows that more than 90 percent of patients who have a self-reported penicillin allergy in their electronic medical record can safely take penicillin after verification testing.

(3)

A 2020 medical research review found, penicillin allergy is estimated to affect approximately 10 percent of the population, and 15 percent of hospitalized patients are labeled with a penicillin allergy.

(4)

Penicillin allergy label is associated with poor patient outcomes including increased hospital length of stay, increased perioperative infections, and overall increased mortality according to the New England Journal of Medicine.

(5)

A 2018 paper in the Journal of Allergy and Clinical Immunology indicates that penicillin allergy evaluation by any means has been shown to be a cost-saving intervention.

(6)

Delabeling penicillin allergy is an important component of antibiotic stewardship and is endorsed by many professional organizations and public health bodies, including the American Academy of Allergy, Asthma & Immunology.

(7)

A 2023 study of adults 65 and older with a penicillin allergy label published in the Annals of Allergy, Asthma & Immunology found that 97 percent were disproved after verification testing.

3.

Penicillin allergy verification and evaluation for seniors

(a)

Initial preventive physical examination

Section 1861(ww) of the Social Security Act (42 U.S.C. 1395x(ww)) is amended—

(1)

In paragraph (1)—

(A)

by inserting penicillin allergy verification and evaluation (as defined in paragraph (5)), after (as defined in paragraph (4)),; and

(2)

in paragraph (2)—

(A)

by redesignating subparagraph (O) as subparagraph (P); and

(B)

by inserting after subparagraph (N) the following new subparagraph:

(O)

Penicillin allergy verification and evaluation.

; and

(3)

by adding at the end the following new paragraph:

(5)

For purposes of paragraph (1), the term penicillin allergy verification and evaluation means—

(A)

identification of individuals reporting a history of penicillin allergy;

(B)

consideration of whether the reported reaction history is consistent with an allergy or hypersensitivity reaction or can be reevaluated;

(C)

the provision of information on the adverse individual and public health impact of a penicillin allergy label; and

(D)

a referral to an allergy or immunology specialist, as appropriate.

.

(b)

Annual wellness visit

Section 1861(hhh)(2) of the Social Security Act (42 U.S.C. 1395x(hhh)(2)) is amended—

(1)

by redesignating subparagraph (I) as subparagraph (J); and

(2)

by inserting after subparagraph (H) the following new subparagraph:

(I)

Penicillin allergy verification and evaluation (as defined in subsection (ww)(5)).

.

(c)

Rule of construction

Nothing in the amendments made by subsection (a) or (b) shall be construed to prohibit separate payment for structured penicillin allergy validation and evaluation services furnished to an individual on the same day as an initial preventive physical examination or an annual wellness visit.

(d)

Effective date

The amendments made by this section shall apply to examinations and visits furnished on or after January 1, 2025.